EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte Studie

Cognitive Outcome after Acute Spontaneous Intracerebral Hemorrhage: Analysis of the iDEF Randomized Trial

Vasileios-Arsenios Lioutas, Aristeidis H Katsanos, Ashkan Shoamanesh, Farhaan Vahidy, Elizabeth C Heistand, Lydia D Foster, Sharon D Yeatts, Magdy Selim, iDEF investigators

Cerebrovascular Diseases · 2024

DOI: 10.1159/000538415 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cerebrovascular Diseases, 2024. Verfasst von Vasileios-Arsenios Lioutas und 8 weiteren Autor:innen. Beteiligte Einrichtung: Stroke Division, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Cerebral Hemorrhage, Cognition, Cognitive Dysfunction, Deferoxamine. Die Arbeit nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The impact of intracerebral hemorrhage (ICH) on cognition and the determinants of cognitive recovery early after ICH remain elusive. In this post hoc analysis of the intracerebral hemorrhage deferoxamine (iDEF) trial, we examined the trajectories of cognitive impairment and the determinants of early cognitive recovery after ICH.

Methods

We examined baseline factors associated with a 90-day cognitive outcome and constructed generalized linear mixed models to examine the trajectory of cognitive function over time among iDEF participants. Cognition was measured by the Montreal Cognitive Assessment (MoCA) scores on days 7, 30, and 90.

Results

291 were available for analysis under the trial’s modified intention-to-treat definition (38% female, mean age 60.3 ± 12.0 years, median NIHSS 13, IQR 8–18). The median baseline ICH volume was 12.9 IQR (6.4–26.0) mL; 59 (20%) of the ICH cases were lobar, 120 (41%) had intraventricular extension. There was an overall significant increase in total MOCA score with time (p < 0.0001). Total MOCA score increased by an estimated 3.9 points (95% CI: 3.1, 4.7) between the day 7 and day 30 assessments and by an additional 2.9 points (95% CI: 2.2, 3.6) between the day 30 and day 90 assessments. Despite the overall improvement, 134 of 205 (65%) patients with an available 90-day MoCA score remained cognitively impaired with a score <26 on day 90. Older age, higher NIHSS score, baseline ICH volume, intraventricular hemorrhage, and perihematoma edema had an adjusted negative impact on cognitive recovery.

Conclusions

Although ICH survivors exhibit significant improvement of cognitive status over the first 3 months, cognitive performance remains impaired in the majority of patients. Among factors independently associated with worse cognitive recovery, higher baseline ICH, intraventricular blood and perihematomal edema volumes, are potential therapeutic targets that merit further exploration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cerebral HemorrhageCognitionCognitive DysfunctionDeferoxamineAgedFemaleHumansMaleMiddle AgedMental Status and Dementia TestsRecovery of FunctionRisk FactorsTime FactorsTreatment Outcome

Stichwörter der Autor:innen

Brain hemorrhageCognitive impairmentIntracerebral hemorrhageVascular cognitive impairment

Substanzen

Deferoxamine

Autor:innen und Institutionen

  • Stroke Division, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Neurology, McMaster University/Population Health Research Institute, Hamilton, Ontario, Canada.
  • Department of Neurosurgery Houston Methodist, Houston, Texas, USA.
  • Department of Population Health Sciences Weill Cornell Medicine, New York, New York, USA.
  • Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.

Zitieren

APA

Lioutas, V. A., Katsanos, A. H., Shoamanesh, A., Vahidy, F., Heistand, E. C., Foster, L. D., Yeatts, S. D., Selim, M., & iDEF investigators (2024). Cognitive Outcome after Acute Spontaneous Intracerebral Hemorrhage: Analysis of the iDEF Randomized Trial. Cerebrovascular Diseases. https://doi.org/10.1159/000538415

Vancouver

Lioutas VA, Katsanos AH, Shoamanesh A, Vahidy F, Heistand EC, Foster LD, et al. Cognitive Outcome after Acute Spontaneous Intracerebral Hemorrhage: Analysis of the iDEF Randomized Trial. Cerebrovascular Diseases. 2024. doi:10.1159/000538415

BibTeX
@article{Lioutas2024,
  author = {Lioutas, Vasileios-Arsenios and Katsanos, Aristeidis H and Shoamanesh, Ashkan and Vahidy, Farhaan and Heistand, Elizabeth C and Foster, Lydia D and Yeatts, Sharon D and Selim, Magdy and iDEF investigators, iDEF investigators},
  title = {Cognitive Outcome after Acute Spontaneous Intracerebral Hemorrhage: Analysis of the iDEF Randomized Trial},
  journal = {Cerebrovascular Diseases},
  year = {2024},
  doi = {10.1159/000538415}
}
Kostenlos starten →